Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsPayablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Common Equity (2022 - 2025)

CervoMed (CRVO) has disclosed Common Equity for 9 consecutive years, with $18.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 53.52% to $18.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.2 million through Dec 2025, down 53.52% year-over-year, with the annual reading at $18.2 million for FY2025, 53.52% down from the prior year.
  • Common Equity hit $18.2 million in Q4 2025 for CervoMed, down from $26.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $109.3 million in Q2 2024 to a low of -$35.1 million in Q2 2023.
  • Historically, Common Equity has averaged $15.7 million across 4 years, with a median of $22.1 million in 2025.
  • Biggest five-year swings in Common Equity: tumbled 210.22% in 2023 and later surged 431.43% in 2024.
  • Year by year, Common Equity stood at -$33.3 million in 2022, then soared by 122.16% to $7.4 million in 2023, then soared by 431.43% to $39.2 million in 2024, then tumbled by 53.52% to $18.2 million in 2025.
  • Business Quant data shows Common Equity for CRVO at $18.2 million in Q4 2025, $26.0 million in Q3 2025, and $33.4 million in Q2 2025.